share_log

Shaw Communications, Enovix And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

Shaw Communications, Enovix And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

邵氏通信、Enovix和其他一些大型股票在今日盤前交易時段走高
Benzinga Real-time News ·  2022/12/30 07:54

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today's pre-market trading session.

今天上午，美國股指期貨走低。以下是今日盤前交易時段錄得漲幅的一些大盤股。

  • Shaw Communications Inc. (NYSE:SJR) shares jumped 10.3% to $29.11 in pre-market trading. Canada's competition tribunal approved Rogers Communications' $14.8 billion offer for Shaw Communications.
  • Lanvin Group Holdings Limited (NYSE:LANV) gained 8.1% to $9.10 in pre-market trading after gaining 8% on Thursday.
  • Borr Drilling Limited (NYSE:BORR) climbed 6.7% to $5.26 in pre-market trading as the company said it has been awarded new contracts for two of its premium jack-up drilling rigs.
  • 邵逸夫通信公司紐約證券交易所(NYSE：SJR)股價在盤前交易中躍升10.3%，至29.11美元。加拿大競爭法庭批准了羅傑斯通信公司以148億美元收購邵氏通信公司的要約。
  • 朗文集團控股有限公司(紐約證券交易所股票代碼：LANV)在週四上漲8%後，在盤前交易中上漲8.1%，至9.10美元。
  • 博爾鑽探有限公司(紐約證券交易所股票代碼：BORR)在盤前交易中攀升6.7%，至5.26美元，該公司表示，已獲得兩個優質自升式鑽井平臺的新合同。

Don't forget to check out our premarket coverage here .

別忘了在這裡查看我們的售前報道。

  • TH International Limited (NASDAQ:THCH) gained 5.8% to $2.75 in pre-market trading after dropping 20% on Thursday.
  • Enovix Corporation (NYSE:ENVX) climbed 4.8% to $13.22 in pre-market trading.
  • Enovix named Raj Talluri as CEO.
  • TG Therapeutics, Inc. (NASDAQ:TGTX) gained 3.9% to $10.80 in pre-market trading. TG Therapeutics shares jumped 23% on Thursday following FDA approval of ublituximab.
  • TH國際有限公司納斯達克(Sequoia Capital：THCH)在週四下跌20%後，盤前交易中上漲5.8%，至2.75美元。
  • Enovix公司(紐約證券交易所代碼：ENVX)在盤前交易中攀升4.8%，至13.22美元。
  • Enovix任命Raj Talluri為首席執行官。
  • TG治療公司納斯達克(TGTX：TGX)在盤前交易中上漲3.9%，至10.8美元。在FDA批准ublituximab後，TG治療公司的股價週四上漲了23%。

Now Read This: Dow Surges Over 300 Points, Market Volatility Decreases
Don't forget to check out our

現在請閱讀：道瓊恩斯指數飆升超過300點，市場波動性下降
別忘了查看我們的

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論